<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373347</url>
  </required_header>
  <id_info>
    <org_study_id>HEP0006</org_study_id>
    <secondary_id>95521</secondary_id>
    <secondary_id>HEP0006</secondary_id>
    <secondary_id>10767</secondary_id>
    <nct_id>NCT00373347</nct_id>
  </id_info>
  <brief_title>Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma</brief_title>
  <official_title>Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify blood markers that have the ability to diagnose&#xD;
      liver cancer with improved accuracy, so that it can be used alone or in conjunction with&#xD;
      alpha-feto protein (AFP)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently&#xD;
      used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP),&#xD;
      which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and&#xD;
      sensitivity. The purpose of this study is to identify blood markers that have the ability to&#xD;
      diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction&#xD;
      with AFP. The aim of this study is to identify new blood markers of liver cancer that can be&#xD;
      used to increase the rate of accurate diagnosis of this malignancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify new blood markers of liver cancer</measure>
    <time_frame>upto 12 months</time_frame>
    <description>Blood specimens collected through another protocol, Patients would have signed informed consent for that protocol, and agreed to have their blood specimens stored for future research such as this one.</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Liver Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with liver cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated&#xD;
             with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.&#xD;
&#xD;
          -  Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or&#xD;
             nodular hyperplasia.&#xD;
&#xD;
          -  Patients with hepatitis B or hepatitis C viral infections not associated with liver&#xD;
             cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Patients will be excluded if, upon looking through their medical records, information&#xD;
        required for data analysis are missing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel So</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei-Sze Chua</last_name>
    <phone>650-724-3525</phone>
    <email>mchua@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Sze Chua</last_name>
      <phone>650-724-3525</phone>
      <email>mchua@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Clinical Trials Office</last_name>
      <phone>(650) 498-7061</phone>
    </contact_backup>
    <investigator>
      <last_name>Samuel So</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 6, 2006</study_first_submitted>
  <study_first_submitted_qc>September 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

